Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma. Ding Y, Jin K, Su X, Zhang L, et al. J Immunother Cancer 2026;14:e014408.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ding Y, Jin K, Su X, Zhang L, et al. Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma. J Immunother Cancer 2026;14:e014408.
PMID: 42161402